Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of GMI-1271 in Healthy Adults
NCT02271113Phase 1Completed
- Sponsor
- GlycoMimetics
- Start
- Oct 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of uproleselan in venous thromboembolism (VTE) (3 arms), sponsored by GlycoMimetics. Primary endpoints: Number, Type, and Severity of Adverse Events and Review of lab results as a measure of Pharmacokinetics. Started Oct 2014; status: completed.
02
Drugs
uproleselan
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT02271113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02271113.